Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Artesunate for HPV+ CIN2/3
NCT07095478Phase 2Not yet recruiting
- Sponsor
- Metanoic Health
- Start
- Aug 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of artesunate in cervical intraepithelial neoplasia (CIN), sponsored by Metanoic Health. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
artesunate
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT07095478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07095478.